Acceleron Pharma
Cambridge
About Acceleron Pharma
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $1.4B
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2020)
- Ticker: nasdaq:XLRN
- Website: acceleronpharma.com
- Phone: 617-649-9200
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/acceleron-pharma-98499 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.